Salidroside represses ovarian cancer progression by targeting FSP1-dependent ferroptosis
Tingting Hua·Fucheng Ma·Weihui Liu·Li Li·Xiaoyan Zhu·Xuantong Wang·Mayire Tuerxun·Chunxia Zhang·Weizhen Wang·Abudushalamu Abulaite·Zhiying Jia·Yan Ma·Muzaipaer Muhetaer·Xinchun Wu
Emerging evidence suggests that ferroptosis resistance contributes to the ovarian cancer (OC) carcinogenesis. Here, the study identified a tumour promoting factor FSP1 and investigated the role of Salidroside in OC ferroptosis resistance. In vitro, Salidroside alleviated the ferroptosis resistance of OC cells, and promoted the ferroptosis features. In vivo, Salidroside could inhibit OC growth and stimulate the ferroptosis. Furthermore, Salidroside targeted the FSP1 to reduce FSP1 mRNA level, the